CompletedPhase 2

A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel

United States2,366 participantsStarted 2019-01-27

Plain-language summary

The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male and Female ≥40 years of age * Acute Ischemic Stroke or Transient Ischemic Attack * Intracranial or Extracranial Atherosclerotic Plaque proximal to the affected brain area Exclusion Criteria: * Predicted inability to swallow study medication * Any condition that, in the opinion of the Investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding * Use of thrombolytic therapy or mechanical thrombectomy for treatment of index stroke Other protocol defined inclusion/exclusion criteria could apply

What they're measuring

Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by Day 90

Timeframe: From randomization to up to 90 days after randomization

Trial details

NCT IDNCT03766581

SponsorBristol-Myers Squibb

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-03-31

Results submitted2023-03-31

View on ClinicalTrials.gov More Acute Ischemic Stroke trials